NCT05711381View on ClinicalTrials.gov

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions
Renal Impairment
Interventions
DRUG

HM15912

Singe subcutaneous administration of HM15912 0.5 mg/kg

Trial Locations (4)

33014

Clinical Pharmacology of Miami, Miami

Panax Clinical Research, Miami Lakes

37920

AMR Knoxville, Knoxville

92780

Orange County Research Center, Tustin

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05711381 - Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function | Biotech Hunter | Biotech Hunter